Cycle Pharmaceuticals Completes Acquisition of Applied Therapeutics
APLTCAMBRIDGE, England & DETROIT--(BUSINESS WIRE)--Cycle Group Holdings Limited (“Cycle”) is delighted to announce it has completed the acquisition of NASDAQ-listed Applied Therapeutics, Inc. (NASDAQ: APLT; “Applied”), a clinical-stage biopharmaceutical company. Applied’s lead drug candidate, govorestat, is a novel central nervous system (CNS) penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including Classic Galactosemia, Charcot-Marie-Tooth Sorbitol Deh
Applied Therapeutics Shares Letter to Stockholders Recommending Tender of Shares Following Offer Expiration Extension
APLTNEW YORK, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT) (the “Company” or “Applied”), a clinical-stage biopharmaceutical company dedicated to creating transformative treatments for rare diseases, today released the following letter to stockholders regarding the pending tender offer by AT2B, Inc. (“Purchaser”), an indirect wholly owned subsidiary of Cycle Group Holdings Limited (“Cycle”).
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2026
APLTSubmitted two additional U.S. government funding proposals during the quarter, bringing the total proposals to US$137 million
Applied Therapeutics Announces Key Leadership Appointments
APLTNEW YORK, June 17, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced key appointments to its executive leadership team with the promotions of Evan Bailey, MD, to Chief Medical Officer (CMO), effective June 15, 2025, and Dottie Caplan to Executive Vice President (EVP), Patient Advocacy and Government Affairs.
Reported Sunday, Applied Therapeutics Reports 24-Month Data From INSPIRE Trial Showing Govorestat Slows Disease Progression In CMT-SORD, Reinforces Plans For 2025 NDA
APLTRBC Capital Reiterates Sector Perform on Applied Therapeutics, Maintains $1.5 Price Target
APLTApplied Therapeutics Q1 EPS $(0.15) Beats $(0.19) Estimate
APLTApplied Therapeutics To Present Full 12-Month Clinical Results From The INSPIRE Phase 3 Trial Of Govorestat In A Late-Breaking Abstract Selected For Oral Presentation At The Peripheral Nerve Society 2025 Annual Meeting, Being Held May 17-20, 2025 In Edinb
APLTApplied Therapeutics FY 2024 GAAP EPS $(0.76) Beats $(1.37) Estimate
APLTThis Mesoblast Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Monday
APLTWilliam Blair Downgrades Applied Therapeutics to Market Perform
APLTPenny Stock Applied Therapeutics' FDA Troubles Trigger Investor Lawsuit, Shareholders Claim Deception Over Govorestat Clinical Data
APLTAdrian Alexandru files a securities lawsuit against Applied Therapeutics, alleging the company misled investors about clinical trials for govorestat.
RBC Capital Maintains Sector Perform on Applied Therapeutics, Lowers Price Target to $1.5
APLTApplied Therapeutics Names John H. Johnson As Executive Chairman; Shoshana Shendelman Has Stepped Down As Chair And CEO; Les Funtleyder Named As Interim CEO
APLT